Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
The Pharmaceuticals market in CIS is a rapidly growing industry with unique customer preferences and local special circumstances.
Customer preferences: Customers in the CIS region have a strong preference for generic drugs due to their affordability. This preference has been driven by the low purchasing power of the population in the region. Additionally, customers in the CIS region have a high demand for over-the-counter drugs due to the lack of access to healthcare professionals.
Trends in the market: The pharmaceuticals market in CIS is developing rapidly, with a focus on the development of new drugs and expansion of production facilities. The market is also seeing an increase in the number of joint ventures between local and international pharmaceutical companies. This trend has been driven by the need to access new technologies and expertise, as well as to expand into new markets.
Local special circumstances: The CIS region has a unique set of circumstances that impact the pharmaceuticals market. The region is characterized by a high burden of infectious diseases such as tuberculosis and HIV/AIDS, which has led to an increased demand for drugs to treat these conditions. Additionally, the region has a large population of elderly people who require medication for chronic conditions such as hypertension and diabetes.
Underlying macroeconomic factors: The pharmaceuticals market in CIS is influenced by a range of macroeconomic factors. The region has a large population of low-income individuals who have limited access to healthcare. This has created a demand for affordable medicines, which has led to the growth of the generic drug market. Additionally, the region has a large number of pharmaceutical manufacturing facilities, which has helped to drive the growth of the industry. Finally, the region has a relatively low cost of labor, which has made it an attractive location for pharmaceutical companies to set up production facilities.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)